Biotechnology patenting in small countries - strategies for the international marketplace

Research output: Contribution to journalArticle

Abstract

The article investigates the conventional strategy for obtaining international patent protection by starting with the national patent application then converting it to the international Patent Cooperation Treaty (PCT) patent application and filing for a national phase in the jurisdiction(s) of interest, in the context of biotechnology start-ups in small countries. Specifically, we investigate whether such strategy is detrimental or beneficial for the eventual entry to the U.S. market. An empirical study of Lithuanian biotech start-ups is presented, producing evidence that many firms did not benefit from going through the traditional strategy. Eventual strategic choices may depend on the goals the firm wants to achieve, as well as its resources available for international patenting. If the firm intends to license the technology which is the subject matter of the patent application, or attract U.S.- based venture capital, it may benefit from tailoring the patent application to the U.S. and filing there at an early (or at least earlier) stage
Original languageEnglish
Pages (from-to)291-299
JournalBiotechnology Law Report
Volume35
Issue number6
DOIs
Publication statusPublished - 2016

Fingerprint

International Cooperation
biotechnology
Biotechnology
Licensure
Economics
Technology
patent
market
resource
firm

Keywords

  • Biotechnology
  • Patents
  • PCT

Cite this

@article{939d325c75b646139e52425ba62e28b7,
title = "Biotechnology patenting in small countries - strategies for the international marketplace",
abstract = "The article investigates the conventional strategy for obtaining international patent protection by starting with the national patent application then converting it to the international Patent Cooperation Treaty (PCT) patent application and filing for a national phase in the jurisdiction(s) of interest, in the context of biotechnology start-ups in small countries. Specifically, we investigate whether such strategy is detrimental or beneficial for the eventual entry to the U.S. market. An empirical study of Lithuanian biotech start-ups is presented, producing evidence that many firms did not benefit from going through the traditional strategy. Eventual strategic choices may depend on the goals the firm wants to achieve, as well as its resources available for international patenting. If the firm intends to license the technology which is the subject matter of the patent application, or attract U.S.- based venture capital, it may benefit from tailoring the patent application to the U.S. and filing there at an early (or at least earlier) stage",
keywords = "Biotechnology, Patents, PCT",
author = "Mindaugas Kiškis and Tadas Limba",
year = "2016",
doi = "10.1089/blr.2016.29035.mk",
language = "English",
volume = "35",
pages = "291--299",
journal = "Biotechnology Law Report",
issn = "0730-031X",
publisher = "Mary Ann Liebert Inc.",
number = "6",

}

TY - JOUR

T1 - Biotechnology patenting in small countries - strategies for the international marketplace

AU - Kiškis, Mindaugas

AU - Limba, Tadas

PY - 2016

Y1 - 2016

N2 - The article investigates the conventional strategy for obtaining international patent protection by starting with the national patent application then converting it to the international Patent Cooperation Treaty (PCT) patent application and filing for a national phase in the jurisdiction(s) of interest, in the context of biotechnology start-ups in small countries. Specifically, we investigate whether such strategy is detrimental or beneficial for the eventual entry to the U.S. market. An empirical study of Lithuanian biotech start-ups is presented, producing evidence that many firms did not benefit from going through the traditional strategy. Eventual strategic choices may depend on the goals the firm wants to achieve, as well as its resources available for international patenting. If the firm intends to license the technology which is the subject matter of the patent application, or attract U.S.- based venture capital, it may benefit from tailoring the patent application to the U.S. and filing there at an early (or at least earlier) stage

AB - The article investigates the conventional strategy for obtaining international patent protection by starting with the national patent application then converting it to the international Patent Cooperation Treaty (PCT) patent application and filing for a national phase in the jurisdiction(s) of interest, in the context of biotechnology start-ups in small countries. Specifically, we investigate whether such strategy is detrimental or beneficial for the eventual entry to the U.S. market. An empirical study of Lithuanian biotech start-ups is presented, producing evidence that many firms did not benefit from going through the traditional strategy. Eventual strategic choices may depend on the goals the firm wants to achieve, as well as its resources available for international patenting. If the firm intends to license the technology which is the subject matter of the patent application, or attract U.S.- based venture capital, it may benefit from tailoring the patent application to the U.S. and filing there at an early (or at least earlier) stage

KW - Biotechnology

KW - Patents

KW - PCT

U2 - 10.1089/blr.2016.29035.mk

DO - 10.1089/blr.2016.29035.mk

M3 - Article

VL - 35

SP - 291

EP - 299

JO - Biotechnology Law Report

JF - Biotechnology Law Report

SN - 0730-031X

IS - 6

ER -